title: Efficacy of recombinant human erythropoietin therapy started one month after autologous peripheral blood stem cell transplantation.
abstract: On day 30 after autologous peripheral blood stem cell transplantation (PBSCT), 20 patients were randomized to receive either erythropoietin at a dose of 500 U/kg/week s.c. (Epo group) or no treatment (control group). After 3 weeks, hemoglobin (p<0.0001) and serum transferrin receptor (p<0.0001) concentrations were higher in the Epo group. Hb response (+2 g/dL) was achieved in 100% vs 28% (p<0.0001) and Hb correction (> or =13 g/dL) in 70% vs 10% (p=0.0238) of the patients, respectively. This is the first randomized study showing an efficacy of erythropoietin therapy on Hb levels after autologous PBSCT.
authors.forename: Gaëtan
authors.initials: G
authors.lastname: Vanstraelen
authors.forename: Frédéric
authors.initials: F
authors.lastname: Baron
authors.forename: Pascale
authors.initials: P
authors.lastname: Frère
authors.forename: Kaoutar
authors.initials: K
authors.lastname: Hafraoui
authors.forename: Georges
authors.initials: G
authors.lastname: Fillet
authors.forename: Yves
authors.initials: Y
authors.lastname: Beguin
mesh_terms: D000368:Aged; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006402:Hematologic Diseases / Q000097:blood / Q000601:surgery*; D006801:Humans; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods; D011994:Recombinant Proteins; D014182:Transplantation, Autologous
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin